Literature DB >> 30026278

Somatic Editing of Ldlr With Adeno-Associated Viral-CRISPR Is an Efficient Tool for Atherosclerosis Research.

Kelsey E Jarrett1,2, Ciaran Lee3, Marco De Giorgi1, Ayrea Hurley1, Baiba K Gillard4,5, Alexandria M Doerfler1, Ang Li3, Henry J Pownall4,5, Gang Bao3, William R Lagor1.   

Abstract

Objective- Atherosclerosis studies in Ldlr knockout mice require breeding to homozygosity and congenic status on C57BL6/J background, a process that is both time and resource intensive. We aimed to develop a new method for generating atherosclerosis through somatic deletion of Ldlr in livers of adult mice. Approach and Results- Overexpression of PCSK9 (proprotein convertase subtilisin/kexin type 9) is currently used to study atherosclerosis, which promotes degradation of LDLR (low-density lipoprotein receptor) in the liver. We sought to determine whether CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats-associated 9) could also be used to generate atherosclerosis through genetic disruption of Ldlr in adult mice. We engineered adeno-associated viral (AAV) vectors expressing Staphylococcus aureus Cas9 and a guide RNA targeting the Ldlr gene (AAV-CRISPR). Both male and female mice received either (1) saline, (2) AAV-CRISPR, or (3) AAV-hPCSK9 (human PCSK9)-D374Y. A fourth group of germline Ldlr-KO mice was included for comparison. Mice were placed on a Western diet and followed for 20 weeks to assess plasma lipids, PCSK9 protein levels, atherosclerosis, and editing efficiency. Disruption of Ldlr with AAV-CRISPR was robust, resulting in severe hypercholesterolemia and atherosclerotic lesions in the aorta. AAV-hPCSK9 also produced hypercholesterolemia and atherosclerosis as expected. Notable sexual dimorphism was observed, wherein AAV-CRISPR was superior for Ldlr removal in male mice, while AAV-hPCSK9 was more effective in female mice. Conclusions- This all-in-one AAV-CRISPR vector targeting Ldlr is an effective and versatile tool to model atherosclerosis with a single injection and provides a useful alternative to the use of germline Ldlr-KO mice.

Entities:  

Keywords:  CRISPR-Cas systems; atherosclerosis; gene editing; hypercholesterolemia; lipoproteins

Mesh:

Substances:

Year:  2018        PMID: 30026278      PMCID: PMC6202188          DOI: 10.1161/ATVBAHA.118.311221

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  45 in total

1.  Fas-mediated apoptosis causes elimination of virus-specific cytotoxic T cells in the virus-infected liver.

Authors:  Z X Liu; S Govindarajan; S Okamoto; G Dennert
Journal:  J Immunol       Date:  2001-03-01       Impact factor: 5.422

2.  Adeno-associated viruses as liver-directed gene delivery vehicles: focus on lipoprotein metabolism.

Authors:  William R Lagor; Julie C Johnston; Martin Lock; Luk H Vandenberghe; Daniel J Rader
Journal:  Methods Mol Biol       Date:  2013

Review 3.  Recent Developments in Gene Therapy for Homozygous Familial Hypercholesterolemia.

Authors:  Ezim Ajufo; Marina Cuchel
Journal:  Curr Atheroscler Rep       Date:  2016-05       Impact factor: 5.113

4.  Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. adeno-associated viral vectors in vivo.

Authors:  Masataka Suzuki; Terry K Bertin; Geoffrey L Rogers; Racel G Cela; Irene Zolotukhin; Donna J Palmer; Philip Ng; Roland W Herzog; Brendan Lee
Journal:  Mol Ther       Date:  2013-01-15       Impact factor: 11.454

5.  Serum opacity factor unmasks human plasma high-density lipoprotein instability via selective delipidation and apolipoprotein A-I desorption.

Authors:  Baiba K Gillard; Harry S Courtney; John B Massey; Henry J Pownall
Journal:  Biochemistry       Date:  2007-10-17       Impact factor: 3.162

6.  Reduced Blood Lipid Levels With In Vivo CRISPR-Cas9 Base Editing of ANGPTL3.

Authors:  Alexandra C Chadwick; Niklaus H Evitt; Wenjian Lv; Kiran Musunuru
Journal:  Circulation       Date:  2018-02-27       Impact factor: 29.690

7.  Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing.

Authors:  Qiurong Ding; Alanna Strong; Kevin M Patel; Sze-Ling Ng; Bridget S Gosis; Stephanie N Regan; Chad A Cowan; Daniel J Rader; Kiran Musunuru
Journal:  Circ Res       Date:  2014-06-10       Impact factor: 17.367

8.  Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor.

Authors:  Hua Sun; Amin Samarghandi; Ningyan Zhang; Zemin Yao; Momiao Xiong; Ba-Bie Teng
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-05-10       Impact factor: 8.311

9.  In vivo genome editing using Staphylococcus aureus Cas9.

Authors:  F Ann Ran; Le Cong; Winston X Yan; David A Scott; Jonathan S Gootenberg; Andrea J Kriz; Bernd Zetsche; Ophir Shalem; Xuebing Wu; Kira S Makarova; Eugene V Koonin; Phillip A Sharp; Feng Zhang
Journal:  Nature       Date:  2015-04-01       Impact factor: 49.962

10.  Easy quantification of template-directed CRISPR/Cas9 editing.

Authors:  Eva K Brinkman; Arne N Kousholt; Tim Harmsen; Christ Leemans; Tao Chen; Jos Jonkers; Bas van Steensel
Journal:  Nucleic Acids Res       Date:  2018-06-01       Impact factor: 16.971

View more
  34 in total

1.  Targeting proprotein convertase subtilisin/kexin type 9 in mice and monkeys.

Authors:  Ya Wang; Murong Ma; Jian-An Wang; Alan Daugherty; Hong S Lu
Journal:  Curr Opin Lipidol       Date:  2019-04       Impact factor: 4.776

2.  Functional Genomics and CRISPR Applied to Cardiovascular Research and Medicine.

Authors:  Fang Li; Jianting Shi; Hong S Lu; Hanrui Zhang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-08-21       Impact factor: 8.311

3.  Updates on Approaches for Studying Atherosclerosis.

Authors:  Congqing Wu; Alan Daugherty; Hong S Lu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-04       Impact factor: 8.311

4.  Pig and Mouse Models of Hyperlipidemia and Atherosclerosis.

Authors:  Godfrey S Getz; Catherine A Reardon
Journal:  Methods Mol Biol       Date:  2022

5.  AAV8-mediated overexpression of mPCSK9 in liver differs between male and female mice.

Authors:  Aimee E Vozenilek; Cassidy M R Blackburn; Robert M Schilke; Sunitha Chandran; Reneau Castore; Ronald L Klein; Matthew D Woolard
Journal:  Atherosclerosis       Date:  2018-09-08       Impact factor: 5.162

6.  Depletion of essential isoprenoids and ER stress induction following acute liver-specific deletion of HMG-CoA reductase.

Authors:  Marco De Giorgi; Kelsey E Jarrett; Jason C Burton; Alexandria M Doerfler; Ayrea Hurley; Ang Li; Rachel H Hsu; Mia Furgurson; Kalyani R Patel; Jun Han; Christoph H Borchers; William R Lagor
Journal:  J Lipid Res       Date:  2020-10-27       Impact factor: 5.922

Review 7.  Annual Report on Sex in Preclinical Studies: Arteriosclerosis, Thrombosis, and Vascular Biology Publications in 2018.

Authors:  Hong S Lu; Ann Marie Schmidt; Robert A Hegele; Nigel Mackman; Daniel J Rader; Christian Weber; Alan Daugherty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-12-23       Impact factor: 8.311

Review 8.  CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases.

Authors:  Garima Sharma; Ashish Ranjan Sharma; Manojit Bhattacharya; Sang-Soo Lee; Chiranjib Chakraborty
Journal:  Mol Ther       Date:  2020-09-20       Impact factor: 11.454

Review 9.  Twenty Years of Studying AngII (Angiotensin II)-Induced Abdominal Aortic Pathologies in Mice: Continuing Questions and Challenges to Provide Insight Into the Human Disease.

Authors:  Hisashi Sawada (澤田悠); Hong S Lu (吕红); Lisa A Cassis; Alan Daugherty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2022-01-20       Impact factor: 8.311

10.  Targeting the Apoa1 locus for liver-directed gene therapy.

Authors:  Marco De Giorgi; Ang Li; Ayrea Hurley; Mercedes Barzi; Alexandria M Doerfler; Nikitha A Cherayil; Harrison E Smith; Jonathan D Brown; Charles Y Lin; Karl-Dimiter Bissig; Gang Bao; William R Lagor
Journal:  Mol Ther Methods Clin Dev       Date:  2021-04-24       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.